Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDI
September 05, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...